Neuphoria Therapeutics Inc (NEUP) Income Statement
NEUP FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsNEUP revenue and net income
Where NEUP's revenue goes
FY2026Each bar shows an amount and its share of revenue. NEUP kept −1,145.7% of revenue as net income.
NEUP profit margins
NEUP growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −92.5% | — | +4.8% | −13.9% |
| Gross profit | −96.6% | — | — | −20.7% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NEUP quarterly EPS vs estimates
Neuphoria Therapeutics beat the analyst EPS estimate in 4 of the last 6 quarters. Next report: November 13, 2026 (estimate $-0.56).
NEUP income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $15.6M | $0 | $0 | $383,156 | $927,544 | $32,062 | $7.4M | $11.9M | $27.1M |
| Cost of revenue | $662,955 | $662,890 | $662,991 | $671,476 | $16.0M | $1.7M | $0 | $12.1M | $25.4M | $24.2M |
| Gross profit | $511,210 | $15.0M | −$662,991 | −$671,476 | −$10.0M | −$1.3M | $32,062 | $2.7M | −$13.4M | $2.8M |
| Research & development | $3.55B | $9.0M | $14.1M | $19.7M | $23.3M | $4.3M | $4.0M | $6.3M | $18.5M | $18.6M |
| Sales, general & admin | $7.44B | $7.8M | $8.5M | $13.4M | $7.4M | $4.2M | $3.3M | $6.6M | $5.0M | $5.7M |
| Total operating expenses | $10.3M | $16.1M | $17.9M | $33.1M | $23.7M | $11.3M | $6.2M | $20.1M | $24.0M | $32.7M |
| Operating income | −$9.8M | −$1.1M | −$26.8M | −$33.1M | −$31.0M | −$9.0M | −$6.2M | −$10.8M | −$21.3M | −$13.8M |
| Interest income | $665,571 | — | $220,097 | $323,158 | $6,789 | $4,325 | — | — | — | — |
| Interest expense | — | — | — | $29,594 | $26,868 | $1.1M | $1.2M | $1.7M | $1.5M | $1.5M |
| Income before taxes | −$13.6M | −$837,998 | −$15.6M | −$32.4M | −$31.9M | −$6.7M | −$4.1M | −$6.9M | −$19.3M | −$4.8M |
| Income taxes | −$139,173 | −$468,366 | −$87,320 | −$209,471 | −$278,767 | −$140,820 | −$142,654 | −$165,795 | −$852,960 | $401,573 |
| Net income | −$13.5M | −$369,632 | −$15.5M | −$32.2M | −$22.9M | −$6.5M | −$4.9M | −$6.8M | −$18.4M | −$5.2M |
| EBITDA | −$9.1M | −$466,201 | −$26.0M | −$31.5M | −$30.3M | −$4.5M | −$1.2M | −$11.2M | −$22.4M | −$3.8M |
| EPS (diluted) | −$4.22 | −$0.24 | −$34.66 | −$1.36 | −$201.12 | −$0.01 | −$0.01 | −$0.01 | −$0.04 | −$0.01 |
| Gross margin | 43.5% | 95.8% | — | — | −2,604.4% | −136.7% | 100.0% | 36.2% | −112.5% | 10.4% |
| Operating margin | −835.5% | −7.2% | — | — | −8,095.2% | −965.7% | −19,319.3% | −145.5% | −178.2% | −51.0% |
| Net margin | −1,145.7% | −2.4% | — | — | −5,986.9% | −704.5% | −15,255.2% | −91.6% | −154.3% | −19.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $0 | $0 | $0 | $0 | $15.0M | $662,715 | $10.1M | $0 | $0 | $0 | $0 |
| Cost of revenue | $165,683 | $165,695 | $165,789 | $165,792 | $331,144 | $165,431 | $2.8M | $165,713 | $165,685 | $255,175 | $3.0M | $4.8M |
| Gross profit | $1.0M | −$165,695 | −$165,789 | −$165,792 | −$10.5M | $15.0M | $662,715 | −$165,713 | −$165,685 | −$255,175 | −$3.0M | −$4.8M |
| Research & development | $419,783 | $752,550 | $1.0M | $5.7M | $700,570 | $1.6M | $2.8M | $2.8M | $4.6M | $2.8M | $4.4M | $7.5M |
| Sales, general & admin | $1.8M | $2.5M | $3.2M | $2.8M | $1.3M | $1.4M | $4.2M | $2.4M | $3.6M | $2.8M | $5.4M | $5.9M |
| Total operating expenses | $1.2M | $1.0M | $4.1M | $5.7M | $16.77B | $3.0M | $4.4M | $3.4M | $5.5M | $3.7M | $6.7M | $13.3M |
| Operating income | −$163,915 | −$1.2M | −$4.1M | −$8.6M | −$10.4M | $12.0M | $2.5M | −$3.6M | −$8.2M | −$5.7M | −$9.8M | −$13.3M |
| Interest income | $170,093 | $186,171 | $167,311 | $141,996 | — | $12,741 | $30,615 | $36,096 | $26,327 | $52,615 | $54,716 | $86,439 |
| Income before taxes | −$4.9M | −$539,856 | $1.8M | −$15.0M | −$15.0M | $11.2M | −$1.9M | −$936,974 | $14.3M | −$6.5M | −$9.9M | −$13.4M |
| Income taxes | −$34,793 | −$34,793 | −$34,794 | −$52,638 | −$156,847 | −$81,186 | $11,609 | −$132,187 | $34,116 | $38,851 | −$74,723 | −$84,869 |
| Net income | −$4.9M | −$505,063 | $1.9M | −$15.0M | −$14.9M | $11.3M | −$1.9M | −$804,787 | −$2.7M | $11.7M | $8.5M | $4.9M |
| EBITDA | $1,764 | −$1.0M | −$3.3M | −$8.4M | −$10.2M | $12.1M | −$5.2M | −$5.0M | −$8.0M | −$5.3M | −$9.2M | −$12.9M |
| EPS (diluted) | −$0.13 | −$0.09 | $0.41 | −$4.41 | −$5.55 | $6.55 | −$1.23 | −$0.00 | −$0.04 | −$33.98 | −$0.64 | $0.00 |
| Gross margin | 85.9% | — | — | — | — | 100.0% | 100.0% | −1.6% | — | — | — | — |
| Operating margin | −14.0% | — | — | — | — | 79.8% | 382.4% | −35.5% | — | — | — | — |
| Net margin | −417.7% | — | — | — | — | 75.1% | −293.2% | −8.0% | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NEUP's financial statements (latest annual report filed September 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NEUP financial results
In fiscal year 2026 (ended June 30, 2026), Neuphoria Therapeutics reported revenue of $1.2 million, down 92.5% from the year before. It had a net loss of $13.5 million, a net profit margin of −1,145.7%. Diluted earnings per share came to −$4.22. Over five years revenue grew at an average rate of 4.8% a year.
See the NEUP stock overview for the latest quote and news, or the NEUP chart for price history and technical indicators.
NEUP income statement FAQ
What is Neuphoria Therapeutics's annual revenue?
Neuphoria Therapeutics reported total revenue of $1.2 million for fiscal year 2026, which ended on June 30, 2026. That was down 92.5% from $15.6 million the previous year.
Is Neuphoria Therapeutics profitable?
No. Neuphoria Therapeutics reported a net loss of $13.5 million in fiscal 2026, a net profit margin of −1,145.7%; its operating margin was −835.5%.
What is Neuphoria Therapeutics's gross margin?
Neuphoria Therapeutics's gross margin was 43.5% in fiscal 2026: for every $100 of revenue, Neuphoria Therapeutics kept $44 after the direct cost of its products and services.
How much does Neuphoria Therapeutics spend on research and development?
Neuphoria Therapeutics spent $3.5 billion on research and development in fiscal 2026, 301,952.5% of revenue.
How fast is Neuphoria Therapeutics growing?
Revenue grew 4.8% a year on average over the last five fiscal years, from $0.9 million to $1.2 million.
What are Neuphoria Therapeutics's earnings per share?
Neuphoria Therapeutics earned $-4.22 per diluted share in fiscal 2026, compared with $-0.24 a year earlier.
When will Neuphoria Therapeutics report its next earnings?
Neuphoria Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Neuphoria Therapeutics's fiscal year end?
Neuphoria Therapeutics's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on September 18, 2026.